Garon EB, Cho BC, Luft A, Alatorre-Alexander J, et al. A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study. Clin Lung Cancer 2024 Mar 15:S1525-7304(24)00038.
PMID: 38584069